A Look at Third-Party Oncology Clinical Pathways

In order to improve patient outcomes and reduce variations in oncology care, more and more payers and providers are adopting oncology clinical pathways (OCPs) — treatment protocols that aim to provide the optimal cancer care to patients at the lowest cost, according to a recent MMIT webinar. The share of oncologists exposed to third-party oncology pathways increased from 20% in 2015 to 52% in 2021, with one third of oncologists choosing a provider-focused pathway as of the fourth quarter of 2021. Breast cancer, multiple myeloma and non-small cell lung cancer are among the top therapeutic areas managed by third-party pathways.

third-party-oncology-clinical-pathways

SOURCE: “Pathways Utilization Amidst Rising Costs of Oncology Treatments,” MMIT. AIS Health is owned by MMIT.

This infographic was reprinted from AIS Health’s biweekly publication RADAR on Drug Benefits.

Jinghong Chen

Jinghong Chen Reporter

Jinghong produces infographics and data stories on health insurance and specialty pharmacy for AIS Health. She graduated from Missouri School of Journalism with a focus on data journalism and international reporting. Before joining AIS in 2018, she worked at WBEZ, Al Jazeera English and The New York Times Chinese.

Related Posts

a-woman-touching-cellphone-screen
February 2

Economy, IRA, Pharma Competition May Impact Industry in 2023

Read More
businessman-analyzing-company-report-working-with-digital-augmented-reality-graphics
February 2

MMIT Payer Portrait: Blue Cross and Blue Shield of Louisiana

Read More
fda-approved-rubber-stamp-with-fda-and-pills-on-craft-paper
February 2

New Law Could Make Accelerated Approval Stricter, If FDA Enforces It

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today